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The MHC locus on human chromosome 6 harbors the
most polymorphic genes in the human genome, and the
large number of alleles in human populations has permitted
key structural features of MHC class I and class II genes that
influence susceptibility to several human autoimmune diseases
to be delineated. In this issue, Hülsmeyer et al. adds a new
twist to the already rich literature on MHC polymorphisms
and human disease (1). The authors determined the crystal
structures of two HLA-B27 subtypes (B
 
*
 
2705 and B
 
*
 
2709)
with the same self-peptide (pVIPR, derived from vasoactive
intestinal peptide type 1 receptor). These two subtypes are
remarkable in that they differ only at one heavy chain residue
but are differentially associated with susceptibility to anky-
losing spondylitis (AS), a chronic inflammatory joint disease.
The pVIPR peptide bound in a conventional conformation
to both HLA-B27 subtypes but in a second unique confor-
mation to the AS-associated B
 
*
 
2705 subtype. In the con-
ventional binding mode, an arginine at position 5 of the
peptide was solvent exposed and thus available for TCR
recognition. In the second conformation, this arginine instead
formed a salt bridge with a buried polymorphic residue
located at the floor of the binding site (Asp 116) (Fig. 1).
The drastically altered position of this central peptide residue
also changed the conformation of the entire central peptide
segment from positions 3 to 7 (1). A single, buried poly-
morphic MHC class I residue can thus affect the global
conformation of a bound peptide.
 
HLA-B27 and Ankylosing Spondylitis.
 
In 1973, a striking
association between HLA-B27 and AS was reported (2, 3).
Even though susceptibility to many other human diseases
has since been shown to be associated with particular alleles
of MHC class I and/or class II genes, it remains one of the
strongest associations between a MHC gene and a chronic
inflammatory disease. An extensive search failed to identify
other genes in the MHC class I region with a tighter linkage
to AS, leading to the conclusion that the HLA-B gene itself
is responsible. HLA-B27 is associated with AS in different
ethnic groups across the world, and the analysis of HLA-
B27 subtypes in different populations laid the foundation for
the structure-function study by Hülsmeyer et al. (1), since it
resulted in the identification of two HLA-B27 subtypes
(B
 
*
 
2706 and B
 
*
 
2709) that are not associated with suscepti-
bility to the disease (4, 5). Among Caucasians, susceptibility
to AS is associated with the B
 
*
 
2705 and B
 
*
 
2702 subtypes,
whereas other subtypes are very rare. In contrast, the
B
 
*
 
2706 subtype is the most prevalent among Indonesians
(80%) but does not confer susceptibility to AS. This subtype
is of interest, since it differs from the B
 
*
 
2704 subtype that
confers susceptibility to AS in Asian populations at only two
positions at the floor of the binding site, positions 114 and
116 (4). A study on the isolated Sardinian population resulted
in the identification of the B
 
*
 
2709 subtype in 10 of 40
normal HLA-B27
 
 
 
 subjects (25%) but none of the 35
HLA-B27
 
 
 
 AS patients (5). This B27 subtype was studied
by Hülsmeyer et al. (1) because it differs from the common
AS-associated B
 
*
 
2705 subtype only at position 116. Most
HLA-B27 subtypes, including the AS-associated B
 
*
 
2705
subtype, carry a negative charge (aspartic acid) at position
116, whereas tyrosine (B
 
*
 
2706) or histidine (B
 
*
 
2709) are
present at this position in the subtypes not associated with
susceptibility to AS. Both the 114 and 116 polymorphisms
may contribute to the absence of an AS association for the
B
 
*
 
2706 subtype, since the AS-associated B
 
*
 
2707 has a tyrosine
at position 116.
 
Structural Features of HLA-B27 Critical for Peptide Binding.
 
How does HLA-B27 confer susceptibility to AS? Many of
the experimental approaches that are being used to approach
this question are based on the important advances that resulted
from the crystal structure of HLA-B27, reported in 1991
(6). The structure was determined with HLA-B27 mole-
cules purified from a human EBV-transformed B cell line,
and the binding site was thus occupied with a diverse set of
self-peptides. Despite the heterogeneity of the bound pep-
tide pool, the electron density in the binding site could be
interpreted as nonameric peptides that were bound in a
largely extended conformation. Particularly remarkable was
the electron density at the P2 position, since it reached
deep into a hydrophobic pocket that ended near a nega-
tively charged Glu 45 (6). These crystallographic data were
complemented by sequence analysis of eluted peptides: the
identified peptides were nine amino acids in length, and
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remarkably, all of these peptides carried an arginine at posi-
tion 2 (7). Alignment of these self-peptide sequences per-
mitted definition of a HLA-B27 binding motif that has
since been used extensively to identify peptides presented
by this MHC molecule to CD8 T cells.
 
Conformation of Peptides Bound to HLA-B27.
 
The
HLA-A2 and HLA-B27 structures also revealed the general
mechanism by which peptides are anchored in the binding
site. Two clusters of conserved amino acids, one at each
end of the peptide-binding groove, are positioned to con-
tact polar atoms of the main chain of the first two and the
last two amino acids of the peptide (6, 8). Although the po-
sition of the terminal peptide residues is thus fixed, a sub-
stantial degree of conformational flexibility is possible for
the central peptide segment, as shown dramatically by the
two conformations of pVIPR bound to HLA-B
 
*
 
2705 (Fig.
1). In both the conventional and unconventional pVIPR
peptide conformations observed in the structure, the elec-
tron density for the main chain and side chains are virtually
identical for the NH
 
2
 
- and COOH-terminal segments (P1
Arg, P2 Arg, P8 His, and P9 Leu). However, each side
chain in the central P3 to P7 segment is positioned differ-
ently in the two pVIPR peptide conformations. The inter-
action of P5 Arg with the 116 Asp at the floor of the pep-
tide-binding site in the nonconventional conformation
thereby drastically alters the shape and charge distribution
in the central peptide segment accessible to the T cell re-
ceptor. Hülsmeyer et al. thus demonstrate for the first time
that the same peptide can be bound by a MHC class I mol-
ecule in two grossly different conformations due to a poly-
morphic residue located on the floor of the binding site (1).
Comparison of the structures of HLA-A2 with five differ-
ent viral peptides had shown that the central peptide seg-
ment differed in its conformation and the positioning of the
peptide side chains among all viral peptides and that this
conformational flexibility contributes to the antigenic iden-
tity of each MHC class I–bound peptide (8). Similar find-
ings have been made for murine MHC class I–peptide
complexes, indicating that such conformational flexibility is
a general property of peptide binding by MHC class I mol-
ecules (9). The conformation of the bound peptide is also
dependent on peptide length, since the position of the pep-
tide termini is typically fixed. The most dramatic example
is the structure of a rat MHC class I molecule with a 13-
residue peptide in which the central peptide segment
bulges out of the binding site. This central peptide segment
was highly flexible, since it assumed different conforma-
tions that were stabilized by crystal contacts in the two
molecules of the asymmetric unit (10). Such grossly differ-
ent peptide conformations are not likely to occur in MHC
class II–peptide complexes, due to fundamental differences
in the anchoring of peptides between MHC class I and class
II proteins: conserved residues of the MHC class II binding
site form hydrogen bonds along the length of the peptide
backbone, and not only at the termini, and thus force the
peptide into an extended conformation (11).
Figure 1. Two distinct conformations of the pVIPR peptide in the binding site of HLA-B27. Two HLA-B27 subtypes that are differentially associated
with susceptibility to AS were crystallized with a self-peptide (pVIPR). The peptide bound in a conventional conformation (termed p4 , blue) to both
B27 subtypes but also in a novel conformation (termed p6 , pink) to the AS-associated B*2705 subtype. In the novel conformation, the arginine at position
5 of the peptide formed a salt bridge with Asp 116 located on the floor of the peptide-binding site, the only residue that differs between the B*2705 and
B*2709 subtypes. The heavy chain  1 helix and the floor of the peptide-binding site are shown (gray), whereas the  2 helix has been cut away to provide
better visibility of the peptide. 
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T Cell Receptor Recognition of HLA-B27–Peptide Com-
plexes.
 
The study also provides evidence that the alterna-
tive pVIPR peptide conformation affects T cell receptor
recognition. One of 39 CTL lines recognized pVIPR only
in the context of B
 
*
 
2705, but not B
 
*
 
2709, and this line
may therefore recognize only the alternative peptide con-
formation. In addition, 15.4% of the CTL lines responded
more vigorously when the peptide was presented by
B
 
*
 
2705 rather than B
 
*
 
2709, even though the peptide
bound with higher affinity to B
 
*
 
2709. Previous studies had
demonstrated a higher frequency of pVIPR-reactive CD8
T cells in subjects with the B
 
*
 
2705 than the B
 
*
 
2709 allele,
again suggesting that the alternative peptide conformation
is recognized by T cells (12). Since the data presented in
the current study were based on polyclonal cell lines in
which CD8 T cells reactive with either peptide conforma-
tion may be present, the frequency of CD8 T cells that rec-
ognize the alternative peptide conformation may be under-
estimated. Particularly valuable would be the analysis of
CD8 T cell clones, since such an analysis would demon-
strate what fraction of CD8 T cells recognize the conven-
tional versus the alternative conformation of pVIPR. This
issue could also be addressed using tetramers of B
 
*
 
2705 and
B
 
*
 
2709 with bound pVIPR. A particularly interesting
question with respect to the pathogenesis of AS is whether
the abundance of the peptide in the conventional versus
the alternative conformation differs between subpopula-
tions of antigen-presenting cells and depends on their acti-
vation/differentiation state.
 
HLA-B27 and Human Disease.
 
Sequence analysis of
peptides bound to B
 
*
 
2705 and B
 
*
 
2709 has demonstrated
that the polymorphic 116 residue also influences the reper-
toire of peptides that is bound. B
 
*
 
2705 shared 79% of its
peptide repertoire with B
 
*
 
2709, and all B
 
*
 
2705 ligands that
were not bound by B
 
*
 
2709 had COOH-terminal basic or
tyrosine residues (13). This polymorphism may, therefore,
influence susceptibility to AS and reactive arthritis by two
mechanisms: differential binding of peptides or induction
of alternative peptide conformations, as described by
Hülsmeyer et al. (1). Further work is thus required to de-
termine which of these mechanisms is responsible for the
differential association of these closely related B27 alleles
with susceptibility to AS.
How common are peptides that bind to HLA-B27 in is
this novel conformation? The minimal requirements for
such a peptide are an arginine at P5 that can form a salt
bridge with Asp 116, an arginine at the P2 anchor position,
and the presence of an aliphatic residue at the P9 position
(for example, xRxxRxxxL; preferences at secondary an-
chor residues not taken into consideration). In the structure
of B
 
*
 
2705 with pVIPR, the P9 leucine side chain is too
short to engage Asp 116, permitting the formation of a bi-
dendate salt bridge between this MHC residue and P5 argi-
nine of the peptide. This peptide conformation would
probably not be possible with an arginine or lysine at the
P9 anchor position and may also be disfavored when a
bulkier aromatic group rather than leucine is present at P9.
Thus, a relatively small subset of peptides that bind to
HLA-B27 may assume such a conformation, since restric-
tions are placed both on the P5 position (1 of 20 possible
side chains) and the P9 position (a small subset of permissi-
ble side chains). A search that also incorporated other fea-
tures of the B27-binding motif indicated that such peptides
are present in human proteins and in antigens from bacteria
known to cause reactive arthritis.
HLA-B27 not only confers susceptibility to AS but also
to reactive arthritis, a condition that can result following
infection with 
 
Chlamydia trachomatis
 
, 
 
Salmonella
 
, 
 
Shigella
 
,
 
Yersinia
 
, or 
 
Campylobacter
 
. Also, 
 
 
 
20–40% of HLA-B27–
positive patients with reactive arthritis progress to AS after
10–20 yr (14). HLA-B27–restricted CD8 T cell clones that
specifically lyse 
 
Yersinia
 
- or 
 
Salmonella
 
-infected target cells
have been isolated from the synovial fluid of patients with
reactive arthritis (15), but it is not known which bacterial
peptide(s) are critical in the pathogenesis and whether T
cell recognition of self-peptides is involved in the chronic
inflammatory stage of the disease.
Previous work on disease-associated MHC polymor-
phisms has provided a number of examples in which key
MHC residues determine the peptide binding preferences
and thus the repertoire of self-peptides that can be pre-
sented. For example, the DQ 
 
 
 
57 polymorphism that is as-
sociated with susceptibility to type 1 diabetes determines
the charge of the P9 pocket of the peptide binding site and
thus has a drastic effect on the peptide repertoire that
can be presented (16, 17). The work by Hülsmeyer et al.
demonstrates a novel potential mechanism by which a dis-
ease-associated MHC polymorphism can affect peptide
presentation: the induction of an alternative peptide con-
formation that changes the peptide surface accessible for
T cell receptor recognition.
 
Fig. 1 was kindly provided by Dr. M. Hülsmeyer and colleagues.
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